Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
about
Focus on renal congestion in heart failureIncreased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic KidneysThe 30-day metric in acute heart failure revisited: data from IN-HF Outcome, an Italian nationwide cardiology registry.Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitusClinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial.A patient with heart failure and worsening kidney functionIn-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.Enlarging Red Blood Cell Distribution Width During Hospitalization Identifies a Very High-Risk Subset of Acutely Decompensated Heart Failure Patients and Adds Valuable Prognostic Information on Top of HemoconcentrationAssociation of gender and length of stay among Puerto Ricans hospitalized with decompensated heart failure.Diagnosis and management of acute heart failureDeterminants of survival following hospitalization for acute heart failure.The acute cardiorenal syndrome type I: considerations on physiology, epidemiology, and therapy.The vulnerable phase after hospitalization for heart failure.The Basic Metabolic Profile in Heart Failure-Marker and Modifier.Perspective on Clinical Application of Biomarkers in AKI.Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial.The top tertile of hematocrit change during hospitalization is associated with lower risk of mortality in acute heart failure patients.Renal dysfunction and heart failure: things are seldom what they seem.Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus.Association of admission and discharge anemia status with outcomes in patients hospitalized for acute decompensated heart failure: Differences between patients with preserved and reduced ejection fraction.Change in plasma volume and prognosis in acute decompensated heart failure: an observational cohort study.An exploratory analysis of the competing effects of aggressive decongestion and high-dose loop diuretic therapy in the DOSE trial.Haemoconcentration as a treatment goal in heart failure: ready for prime time?Lessons learned in acute heart failure.How to tackle congestion in acute heart failure.Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.Improving Postdischarge Outcomes in Acute Heart Failure
P2860
Q26769905-C065A238-614A-400E-887E-1B5CB86ECD8CQ28072939-B8F549B9-6977-4437-9DD8-489F37F2021BQ30960360-A2C622F8-77DE-438E-AFAF-0D3ACFD967ECQ33871321-BED34845-3907-4C9A-B4E5-6B94349DCC0AQ34118880-AA3BBAB9-8495-4EE2-9F8F-E36F608B30DBQ34292920-47851D4A-2F7F-4A43-A0D6-A00907F49070Q37059270-CA452662-6403-4ECC-BD37-5F14E7857240Q37206834-DA0CFDD5-EE7F-45C1-9B13-0B65A85CEEA3Q37605451-4C577CCC-D984-4274-B45F-34EBEA38E5BAQ37680530-B19C669F-C559-4470-8DC5-B74526F632BCQ38183318-A7341AA6-1381-4511-840C-AFCB4D8D0C7AQ38249914-ABEAAD5A-7218-4EAD-B61C-8F45E09D1E64Q38349760-BC90704A-ADC4-436E-8D2E-E499C394A4E3Q38694908-54C6EECA-4C23-47E8-895F-AE7DBFC696D5Q38951140-F57B1639-F34E-440E-A6E3-A5EEE91ACF56Q39055218-56093A5C-281E-400B-A17C-DD6B452A4B30Q41594870-6E1D30DE-747A-40AA-B6A3-7812A2BAC758Q45832388-B9E2C6D9-AD81-4073-9104-9B173BB2EB32Q48130954-4334485D-761F-4D0C-B40E-DC1A58638926Q50209292-474EEAE4-4222-4969-8664-4BC4FC00ED9EQ50585584-6846AB4E-CD05-454B-97BA-75ECADFA841CQ50660691-F8DD39B3-9F6A-427B-85E3-2C468849CBB5Q50914234-263B7633-9966-42D6-A34C-F69515494CD5Q52994251-CD75B97B-BCC0-40F4-BAA2-D0942A64BFACQ55036577-D19FB76F-54D7-4BEF-B29C-B1CCD7A9F481Q55332339-FDD82D58-4A1D-461D-89C0-5EC62A0435BAQ57628371-091B9F15-63C7-4C01-A67F-7484867BA34B
P2860
Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Haemoconcentration, renal func ...... sights from the EVEREST trial.
@ast
Haemoconcentration, renal func ...... sights from the EVEREST trial.
@en
Haemoconcentration, renal func ...... sights from the EVEREST trial.
@nl
type
label
Haemoconcentration, renal func ...... sights from the EVEREST trial.
@ast
Haemoconcentration, renal func ...... sights from the EVEREST trial.
@en
Haemoconcentration, renal func ...... sights from the EVEREST trial.
@nl
prefLabel
Haemoconcentration, renal func ...... sights from the EVEREST trial.
@ast
Haemoconcentration, renal func ...... sights from the EVEREST trial.
@en
Haemoconcentration, renal func ...... sights from the EVEREST trial.
@nl
P2093
P2860
P50
P921
P356
P1476
Haemoconcentration, renal func ...... sights from the EVEREST trial.
@en
P2093
Andrew P Ambrosy
EVEREST Trial investigators
Marvin A Konstam
Muthiah Vaduganathan
Robert J Mentz
Savina Nodari
Stephen J Greene
P2860
P304
P356
10.1093/EURJHF/HFT110
P577
2013-07-11T00:00:00Z